Article Text

Download PDFPDF
Assessment of Risk Factors for 30-Day Hospital Readmission After Surgical Cytoreduction in Epithelial Ovarian Carcinoma
  1. Janelle M. Fauci, MD*,
  2. Kellie E. Schneider, MD*,
  3. Peter J. Frederick, MD*,
  4. Gregory Wilding, PhD,
  5. Joe Consiglio, PhD, MD,
  6. Amelia L. Sutton, PhD, MD*,
  7. Larry C. Kilgore, MD* and
  8. Mack N. Barnes, MD*
  1. *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL; and
  2. Roswell Park Cancer Institute, Buffalo, NY.
  1. Address correspondence and reprint requests to Janelle M. Fauci, MD, University of Alabama at Birmingham, Department of Obstetrics and Gynecology, 1700 6th Ave S, Room 5329A, Birmingham, AL 35249. E-mail: Janelle.fauci{at}obgyn.uab.edu.

Abstract

Objective: To evaluate factors that place epithelial ovarian cancer (EOC) patients at increased risk for hospital readmission.

Methods: A retrospective review of patients diagnosed with EOC undergoing surgical cytoreduction at the University of Alabama at Birmingham from 2001 to 2008 was performed. Patients who required readmission were identified. Demographic data, comorbidities, surgical data including bowel resections, and hospital length of stay were evaluated.

Results: A total of 207 patients were identified. The mean age at diagnosis was 64 years (range, 32-89 years), 58% had optimal debulking (n = 120), and the mean number of comorbidities was 1.3 (range, 0-6). Readmission within 30 days of discharge occurred in 33 (16%) of 207 patients. The readmission group had a statistically higher number of comorbidities (1.75 vs 1.01, P = 0.025). The most common reasons for readmission were small bowel obstruction/ileus, wound complications, and thromboembolic events.

Conclusions: The most common reason for readmission after cytoreductive surgery for EOC is small bowel obstruction/ileus. Studies assessing postoperative disease management programs including nursing telephone follow-up, administration of outpatient intravenous fluids, and continuation of antithrombotic agents may offer opportunities to reduce readmissions.

  • Ovarian carcinoma
  • Readmission
  • Morbidity

Statistics from Altmetric.com

Footnotes

  • Dr Frederick is currently with Roswell Park Cancer Institute, Buffalo, NY.

  • Dr Kilgore is currently with the University of Tennessee, Knoxville, TN.

  • Dr Frederick has no financial or industry support to disclose.

  • The authors have no conflicts of interest to disclose.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.